23andMe joins GLP-1 gold rush

Genetic testing firm closes drug discovery division and announces plans to prescribe GLP-1 drugs for weight loss via telehealth platform.

In its recent quarterly earnings report, consumer genetic testing company 23andMe revealed that it is making a move into the lucrative GLP-1 space, as it seeks to capitalize on the runaway success of drugs like semaglutide, marketed around the world as Ozempic and Wegovy. The company said it intends to launch a telehealth weight loss membership program by the end of the month, allowing members to be prescribed GLP-1 medications.

In a separate filing with the SEC, the company also revealed it has shut down its drug discovery business, although it will continue development of the two immuno-oncology programs currently in clinical development.?

My take on this: GLP-1 receptor agonists, widely recognized for aiding weight loss and diabetes management, also reduce cardiovascular risks and may protect the brain, sparking interest in their potential as "longevity drugs."

The new weight loss membership service will be offered via telehealth provider Lemonaid Health, which 23andMe purchased in 2021. The program will offer participants access to prescription GLP-1 medications along with clinical consultations.

The company also revealed it is commencing a “large-scale genetic research study” into GLP-1s that will seek to identify genetic mechanisms that may affect how the drugs work in different people. The effectiveness of GLP-1s varies from person to person, and some individuals experience adverse side effects, ranging from mild gastrointestinal issues to more serious complications such as pancreatitis or kidney problems. The study’s goal is to uncover whether genetics play a significant role in these varying outcomes.

Discover 23andMe's latest biological age feature and more right HERE.

Thank you for reading! If you enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!